Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts
Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Alemtuzumab (Lemtrada™) is a humanized monoclonal antibody approved in more than 50 countries. Within the European Union, alemtuzumab is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features; in the USA, the indication states that alemtuzumab shou...
Alternative Titles
Full title
Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_swepub_ki_se_500863
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_500863
Other Identifiers
ISSN
1172-7047
E-ISSN
1179-1934
DOI
10.1007/s40263-016-0394-8
